About Associate Professor Jonathan Arnold

Jonathon Arnold is an Associate Professor in the Discipline of Pharmacology and Director of the Cannabinoid Research Group. In 2015 he was appointed Associate Director of Preclinical Research at the Lambert Initiative for Cannabinoid Therapeutics. This research initiative was established as a result of the largest philanthropic donation in the University's history ($33,783,000) made by Barry and Joy Lambert, see http://sydney.edu.au/science/lambert/. A/Prof Arnold’s research has focused on the preclinical pharmacology and therapeutic application of the cannabinoids. His current work examines the efficacy of cannabinoids in various preclinical models of disease including childhood epilepsy, cancer and PTSD. He has published 62 papers which have received over 2000 citations (h-index = 27). His first major discovery was that phytocannabinoids reverse resistance to anticancer drugs by affecting multidrug resistance transporters expressed in cancer cells. He has also isolated several genes that modulate the effects of cannabinoids on the brain which may help explain the varying psychoactive effects that cannabis has on different people. More recently he has examined interplay between CBD and THC, the most abundant phytocannabinoids found in cannabis. He contributed to Australia’s first cannabis potency study, which showed Australian street cannabis is amongst the most potent in the world. Another prominent finding of A/Prof Arnold is that dieting and exercise elevate blood concentrations of THC by dislodging fat-soluble THC from adipose tissue. This phenomenon has far-reaching practical implications providing a means for false positive drug tests in the absence of recent cannabis use and a mechanism of cannabis flashback or re-intoxication.